Acadian Asset Management
MGX icon

Acadian Asset Management’s Metagenomi Therapeutics MGX Stock Holding History

Acadian Asset Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,875
Closed -$105K – 2282
2025
Q4 		$105K Buy
+64,875
New +$140K ﹤0.01% 1667
2025
Q1 		– Sell
-117,338
Closed -$422K – 1839
2024
Q4 		$422K Buy
117,338
+113,643
+3,076% +$274K ﹤0.01% 1112
2024
Q3 		$8K Sell
3,695
-1,745
-32% -$6.05K ﹤0.01% 2033
2024
Q2 		$22K Buy
+5,440
New +$37.4K ﹤0.01% 1671

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management's MGX Position: Q1 2026 in Review

Acadian Asset Management sold out of Metagenomi Therapeutics (MGX) in Q1 2026, closing a stake of 64,875 shares — an estimated $105K sold.

Acadian Asset Management first reported a position in MGX in Q2 2024 and held it in 4 quarters. The position peaked at $422K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Acadian Asset Management reported no remaining Metagenomi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 64,875 Metagenomi Therapeutics shares in Q1 2026, an estimated $105K.
  • Acadian Asset Management first reported a position in Metagenomi Therapeutics in Q2 2024 and held it in 4 quarters.
  • Acadian Asset Management's Metagenomi Therapeutics position peaked at $422K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.